Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
Fiche publication
Date publication
novembre 2022
Journal
JCO precision oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALAC Sophie
Tous les auteurs :
Girod M, Dalle S, Mortier L, Dalac S, Leccia MT, Dutriaux C, Montaudié H, de Quatrebarbes J, Lesimple T, Brunet-Possenti F, Saiag P, Maubec E, Legoupil D, Stoebner PE, Arnault JP, Lefevre W, Lebbe C, Dereure O
Lien Pubmed
Résumé
Mitogen-activating protein kinase inhibitors (MAPKis) are largely used in V600E/K BRAF-mutated metastatic melanomas, but data regarding effectiveness of targeted therapy in patients with rare BRAF mutations and molecular description of these infrequent mutations are scarce.
Mots clés
Humans, Proto-Oncogene Proteins B-raf, genetics, Prospective Studies, Melanoma, drug therapy, Protein Kinase Inhibitors, therapeutic use, Mutation, Neoplasms, Second Primary, Mitogen-Activated Protein Kinase Kinases, genetics
Référence
JCO Precis Oncol. 2022 11;6:e2200075